Phaseline

Companies › SAb Biotherapeutics

SAb Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SAB-142
Human anti-thymocyte immunoglobulin
THRAPhase 2Type 1 DiabetesNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07187531SAB-142Phase 2Type 1 DiabetesMetabolic and endocrineNov 2027

From the company's SEC filings

Cash and short-term investments of $104m on 2026-09-30; operating cash outflow about $50m a year; runway about 25 months at that burn, to Oct 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

THRA (1)

Companies with the same targets

Rare Thyroid Therapeutics International AbbVie

Companies built like this

Rare Thyroid Therapeutics International Yarrow Bioscience Vogenx Zhuhai Rui-Inno Pharmaceutical Technology Tonghua Dongbao Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.